Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

CYT107

Phase 2Small molecule

CYT107 is one of 10 small molecule programs targeting Kaposi Sarcoma. It is currently in Phase 2.

1

Indications

7

Total Trials

1

Active Trials

9

Competitors

Pipeline

Status by Indication[3][1]

Indication

Kaposi SarcomaRecruiting

Kaposi SarcomaPhase 2

Recruiting

Competition

Competitive Landscape

9 competitors in Kaposi Sarcoma

#DrugCompanyPhaseTrials

Ninlaro

Pomalyst

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Inderal

WWyeth-Lederle Vaccines

Inderal

Mylan Pharmaceuticals Inc

Liposomal Doxorubicin

Verzenio

Sephb4-HSA

VVasgene Therapeutics, Inc

CYT107

PDS01ADC

NNational Cancer Institute (NCI)

M7824

EMD Serono Research & Development Institute, Inc.

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2037

Phase 2Recruiting

Kaposi Sarcoma

NCT07308886

Clinical

Trials by Indication[1]

Interleukin2 trials

Randomized Study on Multiple Cycles of Interleukin-7 in HIV Patients Immune Non-responders

Terminated·CCytheris, Inc.·Phase 2·NCT01241643·92 enrolled

Interleukin-7 (CYT107) Treatment of Idiopathic CD4 Lymphocytopenia: Expansion of CD4 T Cells (ICICLE)

Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT00839436·21 enrolled

COVID-192 trials

InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection ( ILIAD-7-US-I )

Terminated·RRevimmune·Phase 2·NCT04442178·26 enrolled

InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic Patients With COVID-19 Infection ( ILIAD-7-US-O )

Terminated·RRevimmune·Phase 2·NCT04426201·10 enrolled

Transplantation1 trial

Recombinant Human Interleukin-7 (CYT107) to Promote T-Cell Recovery After Cord Blood Transplantation

Withdrawn·MM.D. Anderson Cancer Center·Phase 1/2·NCT03600896

Sepsis1 trial

Recombinant Interleukin-7 (CYT107) to Restore Absolute Lymphocyte Counts in Sepsis Patients

Terminated·RRevimmune·Phase 2·NCT03821038·21 enrolled

Kaposi Sarcoma1 trial

Phase II Study of Recombinant Glycosylated Human Interleukin-7 (CYT107) for the Treatment of Kaposi Sarcoma in Participants With HIV and Immune Non-response (REGIMEN-KS HIV)

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT07308886·55 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for CYT107. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CYT107 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CYT107. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Revimmune company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: RRevimmune

Related News